enGene Announces Positive Preliminary Phase I/II Data with EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

enGene Inc. announced positive results from its LEGEND study, a first-in-human Phase I/II clinical trial of EG-70 for the treatment of high-grade non-muscle Invasive bladder cancer in patients with carcinoma in situ that are BCG-unresponsive.